[go: up one dir, main page]

WO2008030260A3 - Treatment of variola viral infections using a tissue factor inhibitor - Google Patents

Treatment of variola viral infections using a tissue factor inhibitor Download PDF

Info

Publication number
WO2008030260A3
WO2008030260A3 PCT/US2006/049186 US2006049186W WO2008030260A3 WO 2008030260 A3 WO2008030260 A3 WO 2008030260A3 US 2006049186 W US2006049186 W US 2006049186W WO 2008030260 A3 WO2008030260 A3 WO 2008030260A3
Authority
WO
WIPO (PCT)
Prior art keywords
variola
treatment
viral infections
tissue factor
factor inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/049186
Other languages
French (fr)
Other versions
WO2008030260A2 (en
Inventor
Sek Chung Michael Fung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of WO2008030260A2 publication Critical patent/WO2008030260A2/en
Anticipated expiration legal-status Critical
Publication of WO2008030260A3 publication Critical patent/WO2008030260A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides novel methods for the treatment of variola viral infections, such as smallpox and monkeypox, by administering a tissue factor inhibitor.
PCT/US2006/049186 2005-12-22 2006-12-21 Treatment of variola viral infections using a tissue factor inhibitor Ceased WO2008030260A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75297205P 2005-12-22 2005-12-22
US60/752,972 2005-12-22
US75805706P 2006-01-11 2006-01-11
US60/758,057 2006-01-11

Publications (2)

Publication Number Publication Date
WO2008030260A2 WO2008030260A2 (en) 2008-03-13
WO2008030260A3 true WO2008030260A3 (en) 2008-06-26

Family

ID=38218698

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/049186 Ceased WO2008030260A2 (en) 2005-12-22 2006-12-21 Treatment of variola viral infections using a tissue factor inhibitor
PCT/US2006/049185 Ceased WO2007076091A2 (en) 2005-12-22 2006-12-21 Treatment of viral infections using a tissue factor inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2006/049185 Ceased WO2007076091A2 (en) 2005-12-22 2006-12-21 Treatment of viral infections using a tissue factor inhibitor

Country Status (1)

Country Link
WO (2) WO2008030260A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12246025B2 (en) 2018-03-21 2025-03-11 Genmab A/S Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US12453781B2 (en) 2018-10-30 2025-10-28 Genmab A/S Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
HRP20171789T1 (en) 2010-06-15 2017-12-29 Genmab A/S HUMAN ANTIBODY ANTIBODIES CONJUGATES WITH TISSUE FACTOR
US10532065B2 (en) 2014-12-19 2020-01-14 Nagasaki University Bisphosphonic acid derivative and application for same
US10430534B2 (en) * 2016-11-30 2019-10-01 Numem Inc. Resistance-based memory compiler
BR112020022642A2 (en) 2018-05-07 2021-02-17 Genmab A/S method to treat cancer in an individual, and, kit
US20230218548A1 (en) * 2020-03-19 2023-07-13 Eumentis Therapeutics, Inc. Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections
CN118772282A (en) * 2023-04-10 2024-10-15 复旦大学 Preparation method and use of nanoantibodies and conjugates targeting tissue factor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274142B1 (en) * 1986-11-04 2001-08-14 Genentech, Inc. Methods of neutralizing coagulation with anti-tissue factor antibodies
US20020168357A1 (en) * 1997-03-10 2002-11-14 Hing C. Wong Antibodies for inhibiting blood coagulation and methods of use thereof
US6593291B1 (en) * 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US6849617B2 (en) * 1999-10-27 2005-02-01 Sunol Molecular Corporation Tissue factor antagonists and methods of use thereof
US20050158325A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20050169927A1 (en) * 2001-10-02 2005-08-04 Novo Nordisk A/S Human tissue factor antibodies
US7132398B2 (en) * 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274142B1 (en) * 1986-11-04 2001-08-14 Genentech, Inc. Methods of neutralizing coagulation with anti-tissue factor antibodies
US6593291B1 (en) * 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US20020168357A1 (en) * 1997-03-10 2002-11-14 Hing C. Wong Antibodies for inhibiting blood coagulation and methods of use thereof
US6849617B2 (en) * 1999-10-27 2005-02-01 Sunol Molecular Corporation Tissue factor antagonists and methods of use thereof
US20050158325A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12246025B2 (en) 2018-03-21 2025-03-11 Genmab A/S Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US12453781B2 (en) 2018-10-30 2025-10-28 Genmab A/S Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate

Also Published As

Publication number Publication date
WO2008030260A2 (en) 2008-03-13
WO2007076091A2 (en) 2007-07-05
WO2007076091A3 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
WO2008127364A3 (en) Antiviral compounds and use thereof
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
AP2212A (en) Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.
WO2007084413A3 (en) Methods for treating hepatitis c
WO2007084435A3 (en) Methods for treating hepatitis c
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2005115398A3 (en) Hiv integrase inhibitors
MX2009013828A (en) Therapeutic compositions and the use thereof.
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
EA200971093A1 (en) THERAPEUTIC COMPOSITIONS AND THEIR APPLICATION
WO2008118849A3 (en) Hiv-1 protease inhibitors
WO2009111633A3 (en) Mercaptan and seleno-mercaptan compounds and methods of using them
WO2005086836A3 (en) Ion channel modulators
WO2010095041A3 (en) Compositions, methods, and kits for treating influenza viral infections
WO2005086895A3 (en) Ion channel modulators
WO2008030260A3 (en) Treatment of variola viral infections using a tissue factor inhibitor
WO2007047608A3 (en) Fibrin targeted therapeutics
WO2005086902A3 (en) Ion channel modulators
WO2005097112A3 (en) Ion channel modulators
EP3996743A4 (en) Engineered vaccinia virus
WO2007005620A3 (en) Arginase ii: a target treatment of aging heart and heart failure
PT2366393E (en) Roflumilast for the treatment of pulmonary hypertension
WO2007092607A3 (en) Treatment of hemorrhagic viral infections using a tissue factor inhibitor
WO2008149863A1 (en) Hair treatment composition
WO2007130499A3 (en) Antiviral agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06851593

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06851593

Country of ref document: EP

Kind code of ref document: A2